Kurs
-2,13%
Likviditet
0,31 MSEK
Prenumeration
Kalender
Est. tid* | ||
2025-10-30 | 07:30 | Kvartalsrapport 2025-Q3 |
2025-07-14 | - | Split QLINEA 1000:1 |
2025-07-10 | - | Kvartalsrapport 2025-Q2 |
2025-06-26 | - | Årsstämma |
2025-05-23 | - | X-dag ordinarie utdelning QLINEA 0.00 SEK |
2025-04-14 | - | Kvartalsrapport 2025-Q1 |
2025-04-03 | - | Extra Bolagsstämma 2025 |
2025-02-28 | - | Bokslutskommuniké 2024 |
2024-11-05 | - | Kvartalsrapport 2024-Q3 |
2024-07-11 | - | Kvartalsrapport 2024-Q2 |
2024-06-28 | - | Årsstämma |
2024-06-12 | - | X-dag ordinarie utdelning QLINEA 0.00 SEK |
2024-05-31 | - | Kvartalsrapport 2024-Q1 |
2024-02-27 | - | Bokslutskommuniké 2023 |
2023-11-02 | - | Kvartalsrapport 2023-Q3 |
2023-07-13 | - | Kvartalsrapport 2023-Q2 |
2023-07-03 | - | Extra Bolagsstämma 2023 |
2023-06-13 | - | Årsstämma |
2023-05-24 | - | X-dag ordinarie utdelning QLINEA 0.00 SEK |
2023-05-04 | - | Kvartalsrapport 2023-Q1 |
2023-02-16 | - | Bokslutskommuniké 2022 |
2022-11-03 | - | Kvartalsrapport 2022-Q3 |
2022-07-14 | - | Kvartalsrapport 2022-Q2 |
2022-05-25 | - | X-dag ordinarie utdelning QLINEA 0.00 SEK |
2022-05-24 | - | Årsstämma |
2022-05-05 | - | Kvartalsrapport 2022-Q1 |
2022-02-17 | - | Bokslutskommuniké 2021 |
2021-11-04 | - | Kvartalsrapport 2021-Q3 |
2021-07-15 | - | Kvartalsrapport 2021-Q2 |
2021-05-26 | - | X-dag ordinarie utdelning QLINEA 0.00 SEK |
2021-05-25 | - | Årsstämma |
2021-05-06 | - | Kvartalsrapport 2021-Q1 |
2021-02-18 | - | Bokslutskommuniké 2020 |
2020-11-05 | - | Kvartalsrapport 2020-Q3 |
2020-07-16 | - | Kvartalsrapport 2020-Q2 |
2020-05-27 | - | X-dag ordinarie utdelning QLINEA 0.00 SEK |
2020-05-26 | - | Årsstämma |
2020-05-07 | - | Kvartalsrapport 2020-Q1 |
2020-02-13 | - | Bokslutskommuniké 2019 |
2019-11-07 | - | Kvartalsrapport 2019-Q3 |
2019-07-18 | - | Kvartalsrapport 2019-Q2 |
2019-05-23 | - | X-dag ordinarie utdelning QLINEA 0.00 SEK |
2019-05-22 | - | Årsstämma |
2019-05-03 | - | Kvartalsrapport 2019-Q1 |
2019-02-14 | - | Bokslutskommuniké 2018 |
Beskrivning
Land | Sverige |
---|---|
Lista | Small Cap Stockholm |
Sektor | Hälsovård |
Industri | Medicinteknik |
Q-linea AB (publ) (OMX: QLINEA) – Q-linea today announces that a university hospital in Belgium has received ethical approval to start a clinical impact study using ASTar.
The study will enroll 60 patients with Gram-negative bacteraemia over a six-month period and aims to explore the impact of ASTar results on time to optimal antibiotic therapy. The study is the first part of a broader research project investigating the benefits of using ASTar with therapeutic drug monitoring.
“Proving the clinical impact of ASTar is a key pillar of our clinical strategy, thus, we are delighted to announce that yet another study will soon be underway. This type of evaluation study is important for the commercial development but also to increase knowledge about benefits with rapid AST in general and ASTar in particular”, said Jonas Jarvius, CEO of Q-linea.
For more information, please contact:
Jonas Jarvius, CEO, Q-linea AB
Jonas.Jarvius@qlinea.com
+46 (0) 70-323 77 60
Anders Lundin, CFO, Q-linea AB
Anders.Lundin@qlinea.com
+46 (0) 70-600 15 20
About Q-linea
Q-linea is an innovative infection diagnostics company that primarily develops instruments and disposables for rapid and reliable infection diagnostics. Our vision is to help save lives by ensuring antibiotics continue to be an effective treatment for future generations. Q-linea develops and delivers preferred solutions for healthcare providers, enabling them to accurately diagnose and treat infectious disease in the shortest possible time. The company's lead product ASTar® is a fully automated instrument for antibiotic susceptibility testing (AST), giving a susceptibility profile within six hours directly from a positive blood culture. For more information, please visit www.qlinea.com.